Pharmaceutical News

RSS

Experimental study shows beneficial effects of Vardenafil on NSAID-induced gastric ulcer

Indomethacin has been proved by epidemiological and experimental studies to be closely associated with peptic ulcer development. Vardenafil is a potent phosphodiesterase 5 inhibitor and its effects on the gastric mucosa havenot been reported.

19 Nov 2009

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus.

19 Nov 2009

Dual niacin-statin therapy improves blood cholesterol levels but does not diminish plaque buildup

The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows.

19 Nov 2009

Once-a-day dosing clinical study of udenafil for erectile dysfunction completed

Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced today that it has completed a 240 patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED).

19 Nov 2009

WHO to launch yellow fever vaccination campaign in West Africa

The WHO on Tuesday announced it would lead a week-long, multi-country vaccination campaign in Africa next week to protect those "deemed at highest risk from yellow fever," Reuters reports.

19 Nov 2009

Humana to commence 'Limited Income Newly Eligible Transition' program for CMS

Effective Jan. 1, 2010, Humana will begin administering the Limited Income Newly Eligible Transition (LI-NET) program for the Centers for Medicare & Medicaid Services (CMS). This program allows individuals who receive Medicare’s low-income subsidy to also receive immediate prescription drug coverage at the point of sale if they are not already enrolled in a Part D plan.

19 Nov 2009

Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported

Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.

19 Nov 2009

New non-alcohol germ protection spray now available in Greater Cleveland

MyClyns, the new non-alcohol germ protection spray, is now available to consumers over the counter throughout Greater Cleveland, one of two cities in the nation chosen as initial test market cities prior to a nationwide product launch.

19 Nov 2009

GAVI Alliance drives down pentavalent vaccine costs, data shows

The "co-ordinated buying policy" of the GAVI Alliance has driven down "[t]he price of a vaccine that helps babies fight off killer diseases," according to data released by the group, Reuters reports. In 2010, the price of pentavalent vaccine, which protects against Hib (Haemophilus influenzae type b), diphtheria, whooping cough, tetanus and hepatitis B, will fall "below $3.0 - a drop of almost $0.50 cents per dose on the 2009 price," according to the news services.

19 Nov 2009

Nicardipine Hydrochloride Injection for short-term treatment of hypertension launched

Caraco Pharmaceutical Laboratories, Ltd. has launched Nicardipine Hydrochloride Injection immediately following Sun Pharma's final approval from the US Food and Drug Administration (FDA).

19 Nov 2009

Tips for lessening needle anxiety

Experts believe fear of needles may be preventing people from rolling up their sleeves for the H1N1 vaccination.

18 Nov 2009

U.S. health officials testify before Senate Committee about H1N1 vaccine campaign

U.S. health officials defended their handling of the country's H1N1 (swine flu) vaccine campaign Tuesday "against criticism that their plan to protect Americans was confusing and over-optimistic," Reuters reports (Fox, 11/17).

18 Nov 2009

Generic and brand-name drug makers face off

"Teva Pharmaceuticals, a leading manufacturer of generic drugs, has been aggressively lobbying Congress to scrap provisions in the health care bills it claims would shut it out of the biologic drug market for too long," Roll Call reports. Lobbyists for the biologics makers have charged, however, that Teva is hypocritical because it is fighting to restrict generic production of its own brand-name product.

18 Nov 2009

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today presented new data on the mechanism of action of elesclomol, a first-in-class oxidative stress inducer, at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in Boston, Mass.

18 Nov 2009

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass.

18 Nov 2009

Pfizer Canada accepts Prix Galien Canada 2009 Innovative Product Award for CHAMPIX

Pfizer Canada accepted the Prix Galien Canada 2009 Innovative Product Award for CHAMPIX (varenicline tartrate), the first prescription treatment for smoking cessation in adults specifically designed to target nicotine addiction. The award was presented last night at a gala in Ottawa recognizing excellence in pharmaceutical research.

18 Nov 2009

Insights into evolving pharmacovigilance trends and their impact on biosimilars and generic products

Experts from PAREXEL International Corporation, a leading global biopharmaceutical services provider, will provide insights into evolving pharmacovigilance trends and their impact on biosimilars and generic products at the World Generic Medicines Congress Americas, being held November 17 - 20, 2009 in Washington, DC.

From Parexel 18 Nov 2009

Sinovac Biotech receives a revised production license for its Panflu.1 vaccine

Sinovac Biotech Ltd., a leading developer and provider of vaccines in China, announced today that it received a revised production license from State Food and Drug Administration for Panflu.1, the Company's H1N1 vaccine. The population has been expanded to include people over 60 years old. The shelf life for PANFLU.1 was extended to one year from six months.

18 Nov 2009

Positive results from REVIVE, a phase 3 pivotal study of avanafil announced

VIVUS, Inc. today announced positive results from REVIVE (TA-301), a phase 3 pivotal study evaluating the safety and efficacy of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED), in 646 patients.

18 Nov 2009

Study: Larger dose of ARBs is more effective in heart failure patients

A larger dose of angiotensin receptor blockers (ARBs) is more effective than a smaller dose in heart failure patients, researchers said at the American Heart Association's Scientific Sessions 2009.

18 Nov 2009

Pharmaceutical News

Experimental study shows beneficial effects of Vardenafil on NSAID-induced gastric ulcer

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Dual niacin-statin therapy improves blood cholesterol levels but does not diminish plaque buildup

Once-a-day dosing clinical study of udenafil for erectile dysfunction completed

WHO to launch yellow fever vaccination campaign in West Africa

Humana to commence 'Limited Income Newly Eligible Transition' program for CMS

Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported

New non-alcohol germ protection spray now available in Greater Cleveland

GAVI Alliance drives down pentavalent vaccine costs, data shows

Nicardipine Hydrochloride Injection for short-term treatment of hypertension launched

Tips for lessening needle anxiety

U.S. health officials testify before Senate Committee about H1N1 vaccine campaign

Generic and brand-name drug makers face off

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

Pfizer Canada accepts Prix Galien Canada 2009 Innovative Product Award for CHAMPIX

Insights into evolving pharmacovigilance trends and their impact on biosimilars and generic products

Sinovac Biotech receives a revised production license for its Panflu.1 vaccine

Positive results from REVIVE, a phase 3 pivotal study of avanafil announced

Study: Larger dose of ARBs is more effective in heart failure patients

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News